USANA Health Sciences Q4 2023 Earnings Report

USANA Health Sciences EPS Results

• Actual EPS: $0.87
• Consensus EPS: $0.52
• Beat/Miss: Beat by +$0.35
• One Year Ago EPS: N/A

USANA Health Sciences Revenue Results

• Actual Revenue: $221.08 million
• Expected Revenue: $206.70 million
• Beat/Miss: Beat by +$14.38 million
• YoY Revenue Growth: N/A

USANA Health Sciences Announcement Details

• Quarter: Q4 2023
• Date: 2/6/2024
• Time: N/A

USANA Health Sciences (NYSE:USNA) develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products. It also provides Celavive, a skin care regimen for various skin care types and ethnicities; and other products for prenatal, infant, and young child age groups. In addition, the company offers materials and online tools to assist associates in building their businesses, as well as in marketing products. It offers its products through retail stores and online. The company has a research collaboration agreement with Beijing University of Chinese Medicine; and National Sports Training Bureau. USANA Health Sciences, Inc. was founded in 1992 and is headquartered in Salt Lake City, Utah.